Lexington, Massachusetts, U.S.A., and Aarhus, Denmark – September 17, 2009 – RainDance Technologies and CLC bio today announced a partnership to develop specialized software for the analysis of targeted resequencing data generated by workflows incorporating RainDance’s Sequence Enrichment Solution and next-generation DNA sequencing platforms.
“The rapid and efficient analysis of genomic data plays an important role in searching for the variants in large populations that cause cancer and other devastating diseases,” said Christopher McNary, President and Chief Executive Officer, RainDance Technologies. “By partnering with CLC bio, we can supply researchers with a solution that leverages the power of our innovative microdroplet-based technology to provide the highest-quality results in a simple yet powerful workflow. This capability will help accelerate the advent of personalized medicine and make profound contributions to health and human disease research,” he said.
CLC bio’s Chief Executive Officer, Thomas Knudsen, continues, “Having decided to focus on high-throughput sequencing technologies several years ago, we’re constantly monitoring the market to identify new and complementary technologies being developed. The sequence enrichment platform from RainDance Technologies is truly innovative, and we are very much looking forward to making it even more valuable in supporting the full scientific workflow of their customers. We are proud to partner with RainDance on helping global science gain new ground.”
As a first step, CLC bio will release an expansion of its CLC Genomics Workbench, enabling scientists to analyze data faster and more effectively when using the RainDance solution for large-scale targeted resequencing studies. The software is already in use by RainDance scientists and will be released for commercial sale later this month.
The CLC bio/RainDance solution can be used with any next-generation sequencing workflow, giving customers the freedom to choose between the Illumina Genome Analyzer, Roche 454, or ABI SOLiD systems.
In the future, the partnership will continue to release specialized reports, data analyses, and workflow support for platform-independent targeted resequencing research that will provide additional value to RainDance customers.
To read more about CLC bio’s customized solutions, go to: http://www.clcbio.com/index.php?id=485
About RainDance Technologies
RainDance Technologies is pioneering the use of high-throughput microdroplet-based analysis in human health and life science research. The company’s core RainStorm™ technology generates millions of discrete droplets that can encapsulate a single molecule, cell or reaction and be digitally analyzed and sorted one at a time. The power, precision and simplicity of microdroplets enable researchers to answer complex questions with unprecedented sensitivity and quantitation. The complete RainDance solution includes automated instrumentation, customizable bioinformatics and high-value consumables and reagents for applications including targeted next-generation DNA sequencing, methylation, digital PCR and single cell analysis. Based in Lexington, Massachusetts, the company supports scientists around the world through its international sales and support operations and a global network of distributors and service providers. For more information, please visit www.RainDanceTech.com.
RainDance, RainStorm, ThunderStorm, Digital Biology are trademarks of RainDance Technologies, Inc. All other brands may be trademarks of their respective holders.
About CLC bio